Grantham, Mayo, Van Otterloo & Co (GMO)
ALT icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Altimmune ALT Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$389K Sell
126,389
-46,170
-27% -$196K ﹤0.01% 568
2025
Q4 		$623K Buy
+172,559
New +$752K ﹤0.01% 562

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s ALT Position: Q1 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) reduced its Altimmune (ALT) stake by 27% in Q1 2026, selling an estimated $196K and leaving 126,389 shares worth $389K. The position accounts for ﹤0.01% of the portfolio, ranked #568.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ALT in Q4 2025 and has held it in 2 quarters since. The position peaked at $623K in Q4 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 126,389 shares of Altimmune worth $389K as of Q1 2026.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 46,170 Altimmune shares in Q1 2026, an estimated $196K.
  • Altimmune made up ﹤0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q1 2026, its #568 holding.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Altimmune in Q4 2025 and has held it in 2 quarters since.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Altimmune position peaked at $623K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.